Cipher Financial Statements From 2010 to 2024

CPH Stock  CAD 14.40  0.16  1.12%   
Cipher Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Cipher Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cipher Pharmaceuticals financial statements helps investors assess Cipher Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cipher Pharmaceuticals' valuation are summarized below:
Gross Profit
16.7 M
Profit Margin
0.5992
Market Capitalization
364.4 M
Enterprise Value Revenue
11.4588
Revenue
26.5 M
We have found one hundred twenty available fundamental signals for Cipher Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Cipher Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 26th of November 2024, Market Cap is likely to drop to about 69.3 M. In addition to that, Enterprise Value is likely to drop to about 60.9 M

Cipher Pharmaceuticals Total Revenue

18.08 Million

Check Cipher Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cipher Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 506.9 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0458 or PTB Ratio of 1.26. Cipher financial statements analysis is a perfect complement when working with Cipher Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Cipher Pharmaceuticals Technical models . Check out the analysis of Cipher Pharmaceuticals Correlation against competitors.

Cipher Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets46.4 M86 M52.4 M
Slightly volatile
Short and Long Term Debt Total335.4 K353 K13.1 M
Pretty Stable
Other Current Liabilities5.9 M5.6 MM
Pretty Stable
Total Current Liabilities10.3 M5.3 M12.2 M
Pretty Stable
Total Stockholder Equity84.5 M80.5 M35.9 M
Slightly volatile
Property Plant And Equipment Net640.4 K402 K777.4 K
Very volatile
Current Deferred Revenue714.3 K519 K839 K
Slightly volatile
Accounts Payable5.7 M4.6 M6.2 M
Pretty Stable
Cash41.8 M39.8 M20.7 M
Slightly volatile
Non Current Assets Total39.6 M37.8 M23 M
Slightly volatile
Cash And Short Term Investments41.8 M39.8 M20.7 M
Slightly volatile
Net ReceivablesM5.1 M9.7 M
Very volatile
Common Stock Shares Outstanding32.1 M25.4 M31.6 M
Slightly volatile
Liabilities And Stockholders Equity46.4 M86 M52.4 M
Slightly volatile
Non Current Liabilities Total246.1 K259 K7.6 M
Pretty Stable
Other Current Assets359.1 K378 K901.5 K
Very volatile
Total Liabilities5.2 M5.5 M19.4 M
Very volatile
Property Plant And Equipment Gross686.7 K756 K836.7 K
Very volatile
Total Current Assets27.9 M48.3 M30.8 M
Pretty Stable
Intangible Assets1.7 M1.8 M8.3 M
Pretty Stable
Common Stock14.7 M18 M22.4 M
Slightly volatile
Other Liabilities4.3 K4.5 K995.3 K
Slightly volatile
Property Plant Equipment788.1 K553.1 K571.9 K
Slightly volatile
Long Term Debt Total279.6 K294.3 K18.3 M
Slightly volatile
Capital Surpluse5.6 M6.2 MM
Slightly volatile
Short and Long Term Debt6.5 M6.9 M20.2 M
Slightly volatile
Non Current Liabilities Other112 K117.9 K569.1 K
Slightly volatile
Net Invested Capital52.7 M80.5 M45 M
Slightly volatile
Net Working Capital45.2 M43 M24 M
Very volatile
Common Stock Total Equity20.4 M21.5 M18.8 M
Slightly volatile
Capital Stock14.6 M18 M18.1 M
Slightly volatile
Capital Lease Obligations335.4 K353 K1.5 M
Slightly volatile

Cipher Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.2 M1.6 M
Very volatile
Selling General Administrative8.8 M5.4 M9.8 M
Pretty Stable
Total Revenue18.1 M21.2 M22.3 M
Pretty Stable
Gross Profit16.3 M17.1 M20.1 M
Very volatile
Other Operating Expenses15.2 M11.1 M16.1 M
Pretty Stable
Research Development418 K440 K1.4 M
Slightly volatile
Total Operating Expenses9.8 M7.1 M13.7 M
Slightly volatile
Cost Of Revenue2.7 M4.1 M2.4 M
Slightly volatile
Selling And Marketing Expenses1.2 M1.3 M2.8 M
Pretty Stable
Interest Income1.5 M1.9 M2.2 M
Slightly volatile
Reconciled Depreciation1.1 M1.2 M999.3 K
Slightly volatile

Cipher Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.6 M28.8 M17.7 M
Pretty Stable
Depreciation1.4 M1.2 M1.6 M
Very volatile
Capital Expenditures136.8 K144 K1.4 M
Very volatile
End Period Cash Flow41.8 M39.8 M20.7 M
Slightly volatile
Issuance Of Capital Stock58.1 K34.2 K84.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.785.02866.8685
Pretty Stable
Dividend Yield0.04580.05140.056
Slightly volatile
PTB Ratio1.261.32166.1256
Pretty Stable
Days Sales Outstanding83.3787.7573178
Slightly volatile
Book Value Per Share3.323.16031.2802
Slightly volatile
Average PayablesM8.5 M8.4 M
Slightly volatile
Capex To Depreciation0.110.11740.9897
Very volatile
PB Ratio1.261.32166.1256
Pretty Stable
EV To Sales3.013.16346.0811
Pretty Stable
Inventory Turnover1.911.36451.9693
Slightly volatile
Days Of Inventory On Hand202267173
Very volatile
Payables Turnover0.450.87710.5666
Slightly volatile
Sales General And Administrative To Revenue0.240.25480.4347
Slightly volatile
Average Inventory891.2 K848.8 K807.6 K
Slightly volatile
Research And Ddevelopement To Revenue0.01980.02080.1045
Slightly volatile
Capex To Revenue0.00650.00680.0651
Pretty Stable
Cash Per Share1.641.56310.7565
Slightly volatile
Days Payables Outstanding395416K
Slightly volatile
Intangibles To Total Assets0.240.20310.3124
Pretty Stable
Current Ratio9.659.19143.5297
Slightly volatile
Receivables Turnover4.374.15922.5318
Slightly volatile
Graham Number7.927.54223.0352
Slightly volatile
Shareholders Equity Per Share3.323.16031.2802
Slightly volatile
Debt To Equity0.450.240.4819
Very volatile
Capex Per Share0.00540.00570.0523
Pretty Stable
Average ReceivablesM2.8 M2.7 M
Pretty Stable
Revenue Per Share0.490.83060.8189
Very volatile
Interest Debt Per Share0.00470.0050.5395
Slightly volatile
Debt To Assets0.160.150.2
Pretty Stable
Operating Cycle482355421
Slightly volatile
Price Book Value Ratio1.261.32166.1256
Pretty Stable
Days Of Payables Outstanding395416K
Slightly volatile
Ebt Per Ebit2.091.09992.0339
Very volatile
Company Equity Multiplier1.321.06841.7938
Pretty Stable
Long Term Debt To Capitalization0.460.320.3669
Slightly volatile
Total Debt To Capitalization0.220.190.2652
Pretty Stable
Debt Equity Ratio0.450.240.4819
Very volatile
Quick Ratio4.448.62363.0871
Pretty Stable
Cash Ratio7.967.58282.4874
Slightly volatile
Days Of Inventory Outstanding202267173
Very volatile
Days Of Sales Outstanding83.3787.7573178
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.00.9910.9175
Very volatile
Price To Book Ratio1.261.32166.1256
Pretty Stable
Fixed Asset Turnover50.0152.6418171
Slightly volatile
Debt Ratio0.160.150.2
Pretty Stable
Price Sales Ratio4.785.02866.8685
Pretty Stable
Asset Turnover0.290.2460.4495
Slightly volatile
Gross Profit Margin0.950.80770.8657
Pretty Stable
Price Fair Value1.261.32166.1256
Pretty Stable

Cipher Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap69.3 M106.4 M105.1 M
Very volatile
Enterprise Value60.9 M66.9 M94.7 M
Very volatile

Cipher Fundamental Market Drivers

Forward Price Earnings11.9617
Cash And Short Term Investments39.8 M

About Cipher Pharmaceuticals Financial Statements

Cipher Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Cipher Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue519 K714.3 K
Total Revenue21.2 M18.1 M
Cost Of Revenue4.1 M2.7 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.25  0.24 
Research And Ddevelopement To Revenue 0.02  0.02 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.83  0.49 
Ebit Per Revenue 0.54  0.57 

Pair Trading with Cipher Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cipher Stock

  0.78AMZN Amazon CDRPairCorr
  0.67BNS Bank of Nova Scotia Earnings Call This WeekPairCorr
  0.65BMO Bank of MontrealPairCorr
  0.45RY Royal Bank Earnings Call Next WeekPairCorr
  0.41TD-PFI Toronto Dominion BankPairCorr
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Cipher Stock

Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.